GBC AG sets MustGrow Biologics price target at CAD 2.51, keeps Buy rating
Bitget2026/09/28 08:00- GBC AG reiterated a Buy on MustGrow Biologics, cutting its target price to CAD 2.51 from CAD 2.70.
- Report cited a first Bayer development milestone, generating CAD 1.36 million of high-margin license revenue in H1 2026.
- TerraSante sales hit about CAD 830,400 by mid-August, up 46% versus full-year 2025, constrained by production ramp delays.
- FY2026 revenue forecast cut to CAD 3.5 million from CAD 4.5 million; EBITDA seen at CAD -4.58 million.
- GBC kept FY2027 revenue at CAD 14.05 million, FY2028 at CAD 31.56 million; EBITDA forecast at CAD -1.08 million, then CAD 8.46 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
